Use of radiometals in nuclear oncology is a rapidly growing field and encompasses a broad
spectrum of radiotracers for imaging via PET (positron emission tomography) or SPECT …

While the development of positron emission tomography (PET) radiopharmaceuticals
closely follows that of traditional drug development, there are several key considerations in …

In recent years, radiometals have been successfully applied to medicine because of their
breadth of decay properties and increased production and availability. Bifunctional chelators …

The development of chelating agents for copper radionuclides in positron emission
tomography radiopharmaceuticals has been a highly active and important area of study in …

H3nota derivatives are among the most studied macrocyclic ligands and are widely used for
metal ion binding in biology and medicine. Despite more than 40 years of chemical research …

Melanoma is a malignant tumor derived from epidermal melanocytes, and it is known for its
aggressiveness, therapeutic resistance, and predisposition for late metastasis. Very late …

Melanocortin-1 receptor (MC1R) and very late antigen-4 (VLA-4, integrin α4β1) are 2
attractive molecular targets for developing peptide radiopharmaceuticals for melanoma …

Tremendous advances over the last several decades in positron emission tomography
(PET) and single photon emission computed tomography (SPECT) allow for targeted …

Positron emission tomography (PET) is an imaging modality used for the noninvasive
assessment of tumor staging and response to therapy. PET with 18F labeled …

Melanoma represents the most aggressive form of skin cancer, and its incidence continues
to rise worldwide. 18 F–FDG PET imaging has transformed diagnostic nuclear medicine and …